par Awada, Ahmad 
;Cardoso, Fatima ;Atalay, G;Giuliani, Rosa;Mano, Max S.;Piccart-Gebhart, Martine
Référence Critical reviews in oncology/hematology, 48, 1, page (45-63)
Publication Publié, 2003-10
;Cardoso, Fatima ;Atalay, G;Giuliani, Rosa;Mano, Max S.;Piccart-Gebhart, Martine Référence Critical reviews in oncology/hematology, 48, 1, page (45-63)
Publication Publié, 2003-10
Article révisé par les pairs
| Résumé : | In recent years, strategy in cancer therapy in general, and breast cancer in particular, has been the use of maximum tolerated doses of toxic non-specific agents as well as the investigation of a range of new agents that specifically target tumor-related molecules, in a variety of biological pathways. The trial of chemotherapy (CT) versus chemotherapy+trastuzumab (Herceptin) in HER-2-overexpressing metastatic breast cancer (MBC) was one of the first to use a biological agent in combination with chemotherapy with success and, together with some trials of taxanes in anthracycline-resistance patients one of the few to demonstrate an overall survival (OS) advantage in MBC. Five main molecular pathways are of particular interest in terms of new drug development in breast cancer: the estrogen receptor (ER) pathway, the tyrosine kinase signal transduction pathway, the cell cycle regulation pathway, the apoptosis pathway and the angiogenesis pathway. This review will focus on new agents, cytotoxic, hormonal and molecular-targeted, which are in advanced clinical stages of development for the treatment of MBC. |
